Vertex Pharmaceuticals won regulatory approval on Monday for a new hepatitis C drug, setting off a marketing battle with Merck over new drugs that are expected to improve the cure rate of the disease and shorten the duration of treatment.

Incivek, as the drug will be called, is expected to be the first big product for Vertex, and the first it will sell on its own.